Jephson Dermatology Centre, South Warwickshire NHS Foundation Trust, Warwick, UK.
Department of Public Health, University of Warwick, Coventry, UK.
Clin Exp Dermatol. 2021 Aug;46(6):1001-1010. doi: 10.1111/ced.14625. Epub 2021 May 1.
Erythroderma (exfoliative dermatitis), first described by Von Hebra in 1868, manifests as a cutaneous inflammatory state, with associated skin barrier and metabolic dysfunctions. The annual incidence of erythroderma is estimated to be 1-2 per 100 000 population in Europe with a male preponderance. Erythroderma may present at birth, or may develop acutely or insidiously (due to progression of an underlying primary pathology, including malignancy). Although there is a broad range of diseases that associate with erythroderma, the vast majority of cases result from pre-existing and chronic dermatoses. In the first part of this two-part concise review, we explore the underlying causes, clinical presentation, pathogenesis and investigation of erythroderma, and suggest potential treatment targets for erythroderma with unknown causes.
红皮病（剥脱性皮炎），由 Von Hebra 于 1868 年首次描述，表现为皮肤炎症状态，伴有皮肤屏障和代谢功能障碍。据估计，欧洲每年每 10 万人中就有 1-2 人患有红皮病，男性发病居多。红皮病可在出生时出现，也可急性或隐匿性发作（由于潜在的原发性疾病进展，包括恶性肿瘤）。虽然有广泛的疾病与红皮病相关，但绝大多数病例是由先前存在的慢性皮肤病引起的。在这篇两部分综述的第一部分中，我们探讨了红皮病的潜在病因、临床表现、发病机制和检查，并为原因不明的红皮病提出了潜在的治疗靶点。
